<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-SQAWTHGS</identifier><date>2016</date><creator>Krajc, Mateja</creator><creator>Škof, Erik</creator><relation>documents/doc/S/URN_NBN_SI_doc-SQAWTHGS_001.pdf</relation><relation>documents/doc/S/URN_NBN_SI_doc-SQAWTHGS_001.txt</relation><format format_type="issue">1</format><format format_type="volume">20</format><format format_type="type">article</format><format format_type="extent">str. 12-14</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">2416763</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-SQAWTHGS</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">jajčniki</subject><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">rak (medicna)</subject><subject language_type_id="slv">tarčna zdravila</subject><title>Lynparza (olaparib)</title><title>novo tarčno zdravilo pri raku jajčnikov</title></Record>